Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $40.90M in the quarter ending September 30, 2024, with 458.83% growth. This brings the company's revenue in the last twelve months to $175.04M, up 146.27% year-over-year. In the year 2023, Adaptimmune Therapeutics had annual revenue of $60.28M with 122.05% growth.

• Revenue (ttm): $175.04M
• Revenue Growth: +146.27%
• P/S Ratio: 0.78
• Revenue / Employee: $389,846
• Employees: 449
• Market Cap: 143.17M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	60.28M	33.13M	122.05%
Dec 31, 2022	27.15M	21.00M	341.50%
Dec 31, 2021	6.15M	2.19M	55.36%
Dec 31, 2020	3.96M	2.84M	252.76%
Dec 31, 2019	1.12M	-58.38M	-98.11%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.